Abstract LB-206: Target validation of C4.4a (LYPD3) as a target for antibody-drug conjugates for the treatment of squamous cell carcinoma of different origin.

Leder, Gabriele, Cao, Yong-Jiang, Linden, Lars · Cancer Research · 2013